Xylometazoline

證據等級: L5

預測適應症: 2 個

Xylometazoline: From an Undocumented Original Indication to Nasal Cavity Disease

One-Sentence Summary

Xylometazoline (DrugBank DB06694) is a topical decongestant compound; however, its original approved indication and detailed mechanism of action are not documented in this evidence pack, and it is currently not marketed in Taiwan. The TxGNN model predicts it may be effective for Nasal Cavity Disease, supported by 2 clinical trials and 7 publications, though most of this evidence is procedural/adjunctive rather than a direct treatment trial.

Quick Overview

Item	Content
Original Indication	Not available — no approved indication text or original_indications entries in evidence pack
Predicted New Indication	Nasal Cavity Disease
TxGNN Prediction Score	99.91%
Evidence Level	L3
US Market Status	Not marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed original mechanism-of-action data (original_moa) is not available in this evidence pack. However, the repurposing rationale attached to the top prediction identifies xylometazoline as an alpha-2 adrenergic agonist: it acts locally on nasal mucosal blood vessels to induce vasoconstriction, reducing mucosal swelling and expanding the nasal airway. This is a well-characterized pharmacological action of the compound class.

The predicted indication — “nasal cavity disease” — is mechanistically consistent with this decongestant action, since reduced mucosal congestion directly addresses the broad symptom category of nasal cavity disease (nasal obstruction, mucosal swelling). However, because original_indications is empty in this pack, it cannot be confirmed whether this represents a genuinely new indication or simply reflects the drug’s already well-known, label-consistent decongestant use. This ambiguity should be resolved before treating the prediction as a novel repurposing signal.

A second, lower-ranked prediction (acute laryngopharyngitis, score 99.89%) follows a similar plausible mechanism — reduced upper airway mucosal congestion may indirectly ease laryngopharyngeal inflammation-related nasal symptoms — but has no supporting clinical trial or literature evidence and is a pure knowledge-graph association (Evidence Level L5, recommendation: Hold).

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06443255	Phase 3	Completed	16	Triple-crossover comparison of cocaine, lidocaine/xylometazoline, and saline for intranasal analgesia during awake fiberoptic nasotracheal intubation; not a direct treatment trial for nasal cavity disease (Grade C relevance).
NCT05072392	N/A	Unknown	80	Evaluated Foley catheter-assisted nasal intubation to reduce nasal bleeding; xylometazoline use is procedural/adjunctive rather than a therapeutic endpoint (Grade C relevance).

Note: both trials relate to peri-procedural nasal decongestion, not to treatment of nasal cavity disease as a clinical condition.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
8740084	1996	RCT (small)	Arzneimittel-Forschung	Double-blind rhinomanometric study comparing tuaminoheptane/N-acetyl-cysteine vs. xylometazoline vs. placebo on nasal resistance in healthy subjects.
24158493	2013	RCT (small, pediatric)	JAMA Otolaryngology–Head & Neck Surgery	Double-blind, placebo-controlled trial of intranasal local anesthetic/decongestant (including xylometazoline) for flexible nasendoscopy in children.
34783482	2021	Review	Vestnik Otorinolaringologii	Reviews treatment approaches for inflammatory nasal/paranasal sinus disease in elderly patients, including combined decongestant nasal sprays.
24023995	2013	Cohort/Physiological study	Korean Journal of Anesthesiology	Compared xylometazoline spray vs. epinephrine gauze packing for nasal cavity expansion before nasotracheal intubation.
1281924	1992	Physiological study	Rhinology	Investigated nasal airflow asymmetry and the effect of topical xylometazoline decongestant on nasal airway resistance.
22427029	2013	Prospective comparative study	Eur Arch Otorhinolaryngol	Compared cotton pledget packing vs. topical spray (including xylometazoline) for nasal preparation before endoscopy.
20632242	2010	Animal/comparative anatomy study	Pneumologie	Evaluated xylometazoline and surgical turbinectomy effects on nasal airflow resistance in brachycephalic dogs.

US Market Information

No license records are available — xylometazoline is currently not marketed in Taiwan (0 NDAs on file in this evidence pack).

Safety Considerations

Please refer to the package insert for safety information.

Note: Taiwan-specific labeling (warnings/contraindications) for this product is flagged as a Blocking data gap (DG001) — TFDA package insert data has not yet been retrieved and parsed. This must be resolved before any safety evaluation (S1 stage) can proceed. No drug-drug interaction records were found in the queried database (query_status: not_found).

Conclusion and Next Steps

Decision: Hold

Rationale: The top prediction (nasal cavity disease) has only Evidence Level L3, and the supporting clinical trials/literature are largely procedural or adjunctive (e.g., pre-intubation decongestion, endoscopy preparation) rather than direct treatment trials for nasal cavity disease as a condition. Combined with a Blocking safety data gap (no TFDA label data) and unresolved ambiguity over whether this is genuinely a new indication, the evidence does not yet support proceeding.

To proceed, the following is needed:

Retrieve and parse TFDA package insert (warnings, contraindications) — currently blocking (DG001)
Confirm original approved indication(s) and MOA via DrugBank to determine if “nasal cavity disease” is a novel repurposing signal or an existing label use (DG002)
Identify clinical trials/literature directly evaluating xylometazoline as a treatment for nasal cavity disease, rather than as a peri-procedural adjunct
Given the second candidate (acute laryngopharyngitis) has zero supporting evidence, it should remain at Hold/S0 pending any literature or trial data
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.